# Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

> **NCT05786924** · PHASE1,PHASE2 · RECRUITING · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 554 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer
- Histiocytic Neoplasm
- Histiocytosis
- BRAF Gene Mutation
- BRAF V600E
- BRAF V600 Mutation
- BRAF Mutation-Related Tumors
- BRAF
- Metastatic Lung Non-Small Cell Carcinoma
- Metastatic Lung Cancer
- Recurrent Lung Cancer
- Recurrent Lung Non-Small Cell Carcinoma
- NSCLC
- Solid Tumor
- Solid Carcinoma
- KRAS G12D
- KRAS G12V
- KRAS Mutation-Related Tumors
- NRAS Gene Mutation
- Thyroid Cancer
- Thyroid Carcinoma
- Colorectal Cancer
- Colorectal Carcinoma
- Recurrent Histiocytic and Dendritic Cell Neoplasm
- Brain Metastases
- Recurrent NSCLC
- KRAS G13C
- Acquired Resistance to KRAS G12C Inhibitor
- KRAS G12A
- KRAS G12F
- KRAS G12R
- KRAS G13D

## Interventions

- **DRUG:** S241656
- **DRUG:** FOLFOX6/FOLFOX7
- **DRUG:** FOLFIRI
- **DRUG:** Cetuximab
- **DRUG:** Panitumumab
- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT05786924
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-18
- **Primary completion:** 2028-06
- **Final completion:** 2028-06
- **Target enrollment:** 554 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05786924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05786924, "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05786924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*